Trade BioNTech SE
BioNTech SE (BYE-on tek; short for new biopharmaceutical technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for the patient's approach to disease treatment. It develops pharmaceutical candidates based on reponic acid messenger (RNA) for use as individual cancer immunotherapy treatments, as vaccines against infectious diseases and as protein alternative therapies for rare diseases, and also engineering of cell therapy, novel antibodies and small immunomodulators molecules as treatment options for cancer. A human therapeutic company based on vein management has developed to offer individual DNA-based myrna cancer immunotherapy for clinical trials and establish its own manufacturing process. In 2020 BioNTech, in conjunction with Pfizer, developed the BNT162b2 RNA vaccine for the prevention of COVID-19 infection, which provides 95% efficacy. On 2 December 2020, the UK government granted temporary permission by BNT 162b2 for vaccinations within the UK. It was the first flexible vaccine ever allowed. A few days later, the vaccine also received emergency approval in the United States, Canada and Switzerland. On 21 December 2020, the European Commission approved the BioNTech/Pfizer coronary virus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).